Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
The FDA's decision on the Novavax COVID-19 vaccine could come in weeks
11:48am, Friday, 27'th May 2022 MarketWatch
The company's protein-based shot has been authorized or approved in several other countries, including the U.K. and Singapore.
Dividend stocks have trounced the market this year. Here are 15 high-yield stocks expected to raise payouts the most through 2024
08:19am, Friday, 27'th May 2022 MarketWatch
Investors have favored companies with healthy cash flows as the central bank dials back stimulus.
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?
11:51am, Thursday, 26'th May 2022 Zacks Investment Research
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
11:42am, Thursday, 26'th May 2022 The Motley Fool
New treatments will step in to replace blockbuster eye medication EYLEA.
Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?
09:02am, Thursday, 26'th May 2022
Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.
We've Only Just Begun
09:17am, Wednesday, 25'th May 2022 Seeking Alpha
Today's stock bear market has only just begun. Elevate your investment strategy to find opportunities that remain abundant within the broader market. Read more.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
10:20am, Tuesday, 24'th May 2022 Zacks Investment Research
Smart Beta ETF report for PBE
Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA
03:46pm, Monday, 23'rd May 2022 Zacks Investment Research
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
Analyst Ratings for Amgen
03:26pm, Monday, 23'rd May 2022 Benzinga
Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
6
0
0
Last 30D
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
02:33pm, Monday, 23'rd May 2022 Benzinga
Upgrades
According to Morgan Stanley, the prior rating for Motorola Solutions Inc (NYSE:MSI) was changed from Equal-Weight to Overweight. Motorola Solns earned $1.70 in the first quarter, compared to
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
02:30pm, Monday, 23'rd May 2022 The Motley Fool
J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.
Could This Biosimilar Drug Candidate Create a Blockbuster for Amgen?
10:30am, Monday, 23'rd May 2022
J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.
Amgen: Safe Harbor In Turbulent Times
06:51am, Saturday, 21'st May 2022
Amgen can be a cornerstone in your portfolio due to its fortress financial strength, secular support, and strong profitability. At its present price levels, a dividend discount reveals a very asymmetr
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
06:17pm, Friday, 20'th May 2022 Zacks Investment Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
04:54pm, Friday, 20'th May 2022 Zacks Investment Research
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
